OTCMKTS:HLUYY H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free HLUYY Stock Alerts $22.00 -0.01 (-0.02%) (As of 08/9/2022) Add Compare Share Share Today's Range$22.00▼$24.0050-Day Range$22.00▼$22.0052-Week Range$10.00▼$31.55Volume7,500 shsAverage Volume1,758 shsMarket Capitalization$21.91 billionP/E Ratio25.00Dividend Yield0.91%Price TargetN/A Stock AnalysisStock Analysis Get H. Lundbeck A/S alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.Read More HLUYY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLUYY Stock News HeadlinesMay 17, 2024 | morningstar.comH. Lundbeck AS Class A HLUN AMay 2, 2024 | msn.comBluey’s Big Play coming to Buddy Holly Hall in AugustApril 26, 2024 | seekingalpha.comGIFLF Grifols, S.A.April 22, 2024 | msn.comNew Hampshire's 'Kid Conservationist' joins 'Jennifer Hudson Show' for Earth DayApril 16, 2024 | finance.yahoo.comH. Lundbeck A/S (LDBB.F)April 15, 2024 | msn.com‘Vanished’: 25 years since Nathan Edberg’s vehicle was found abandoned in Vadnais Heights, search for answers continuesMarch 25, 2024 | fool.comH. Lundbeck A/s (OTC: HLUYY)February 23, 2024 | investing.comH Lundbeck A/S ADR (HLUYY)February 11, 2024 | msn.comWWE: Becky Lynch gives fans a preview of what to expect from her bookJanuary 19, 2024 | msn.comA Chilling New Twist in the Lindbergh Baby Mystery Could Actually Flip the VerdictAugust 23, 2023 | wsj.comH. Lundbeck A/S Cl AAugust 11, 2023 | msn.com‘Finding W.H. Hudson’ Review: The Enigmatic BirdmanAugust 8, 2023 | nytimes.comTo Have and to Hold, Even if You Turn Into a Literal SharkJuly 18, 2023 | uk.investing.comH Lundbeck B (0ND5)May 12, 2023 | msn.comH. Lundbeck A/S reports Q1 resultsFebruary 8, 2023 | msn.comH. Lundbeck A/S reports FY resultsNovember 24, 2022 | finance.yahoo.comH. Lundbeck A/S (HLUN-B.CO)October 20, 2022 | investing.comH Lundbeck B (HLUNb)September 14, 2022 | msn.comMonica Lewinsky's Response to Death of Clinton Prosecutor Ken Starr PraisedSeptember 13, 2022 | msn.comWatch Lucid's Boss Spend an Hour Explaining How the Air's Motor WorksSeptember 9, 2022 | msn.comEveryone's Saying The Same Thing About Odell Beckham Jr. TonightSeptember 6, 2022 | msn.comSlain Memphis jogger Eliza Fletcher was a 2010 graduate of Baylor UniversitySeptember 3, 2022 | msn.comFormer Lutz Children’s Museum director busted on child pornography chargesSeptember 2, 2022 | yahoo.comFormer children’s museum director pleads guilty to child pornography chargesSeptember 2, 2022 | msn.comFormer executive director for Manchester children's museum pleads guilty to distributing child pornographySee More Headlines Receive HLUYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2015Today6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:HLUYY CUSIPN/A CIKN/A Webwww.lundbeck.com Phone(453) 630-1311Fax45-3630-1940Employees5,348Year Founded1915Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio25.00 Forward P/E Ratio10.48 P/E GrowthN/ANet Income$209.69 million Net Margins6.74% Pretax Margin7.83% Return on Equity13.74% Return on Assets7.16% Debt Debt-to-Equity Ratio0.32 Current Ratio1.15 Quick Ratio0.71 Sales & Book Value Annual Sales$2.59 billion Price / Sales8.45 Cash Flow$3.36 per share Price / Cash Flow6.54 Book Value$14.60 per share Price / Book1.51Miscellaneous Outstanding Shares995,741,000Free FloatN/AMarket Cap$21.91 billion OptionableNot Optionable Beta0.68 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Deborah Dunsire M.D. (Age 60)Pres & CEO Comp: $7.16MMr. Jacob Tolstrup (Age 50)Exec. VP of Commercial Operations & Chief Commercial Officer Comp: $888.17kMr. Lars Bang (Age 60)Exec. VP of Product Devel. & Supply Comp: $915.5kDr. Per Johan Luthman (Age 63)Exec. VP of R&D Comp: $901.84kMr. Bjorn R. MogensenSr. VP Group Fin.Dr. Tarek Samad Ph.D.Sr. VP & Head of ResearchMr. Palle Holm OlesenChief Specialist & VP of Investor RelationsMs. Elise Hauge (Age 55)Exec. VP of People & Communication Mr. Ole Chrintz (Age 64)Sr. VP of International Markets Mr. Keld Flintholm Jorgensen (Age 51)Exec. VP of Corp. Strategy & Bus. Devel. More ExecutivesKey CompetitorsBYDOTCMKTS:BYDDYIberdrolaOTCMKTS:IBDRYShin-Etsu ChemicalOTCMKTS:SHECYGlencoreOTCMKTS:GLNCYVinciOTCMKTS:VCISYView All Competitors Should I Buy H. Lundbeck A/S Stock? HLUYY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in H. Lundbeck A/S: Recent positive developments in the company's pipeline, indicating potential for future growth and innovation. Strong financial performance with consistent revenue growth and profitability, providing stability for investors. Current stock price showing an upward trend, suggesting market confidence and potential for capital appreciation. Strategic partnerships and collaborations that could lead to new market opportunities and increased market share. Focus on research and development, ensuring a competitive edge in the pharmaceutical industry and potential for breakthrough products. Cons Investors should be bearish about investing in H. Lundbeck A/S for these reasons: Market volatility and regulatory challenges in the pharmaceutical sector could impact the company's performance and stock value. Dependency on a few key products for a significant portion of revenue, posing a risk if any of these products face setbacks. Competition from generic drug manufacturers affecting pricing and market share of H. Lundbeck A/S products. Currency exchange rate fluctuations impacting international sales and profitability. Uncertainty in global economic conditions affecting overall demand for pharmaceutical products and healthcare services. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these H. Lundbeck A/S pros and cons to contact@marketbeat.com. HLUYY Stock Analysis - Frequently Asked Questions Should I buy or sell H. Lundbeck A/S stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" HLUYY shares. View HLUYY analyst ratings or view top-rated stocks. How have HLUYY shares performed in 2024? H. Lundbeck A/S's stock was trading at $22.00 on January 1st, 2024. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00. View the best growth stocks for 2024 here. How were H. Lundbeck A/S's earnings last quarter? H. Lundbeck A/S (OTCMKTS:HLUYY) released its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.01 by $0.16. The firm earned $547.05 million during the quarter, compared to the consensus estimate of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%. Is H. Lundbeck A/S a good dividend stock? H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for HLUYY. How do I buy shares of H. Lundbeck A/S? Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does H. Lundbeck A/S have any subsidiaries? The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.Read More This page (OTCMKTS:HLUYY) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H. Lundbeck A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share H. Lundbeck A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.